Corbus Pharmaceuticals Holdings, Inc. (CRBP) — Current Report

AI-Powered SEC Filing Analysis

← All CRBP filings
Latest Current Report Filed: 2026-05-14

Key Insights

  • Corbus appointed Brent Pfeiffenberger, an experienced pharma executive with significant oncology commercial leadership at Bristol-Myers Squibb and current CEO/Chairman of Century Therapeutics, to its board, expanding it to seven members and signaling potential strategic focus on oncology or commercial expansion.
  • Stockholders approved a 2024 Equity Compensation Plan amendment increasing authorized shares by 3 million to 5 million total, providing the company with enhanced flexibility for employee equity incentives and potential future acquisitions or strategic transactions.
  • The board determined Pfeiffenberger meets independence requirements under Nasdaq rules, ensuring proper governance structure, though his initial equity grant terms remain pending board determination and will be disclosed in a future 8-K amendment.
Filing tone (AI): Positive
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-05-14. In the app, any new 10-K, 10-Q or 8-K is analyzed the moment you open it.

Download on theApp Store Get it onGoogle Play
Get it on Google Play Open in app →

Earlier Current Report filings

Filed: 2026-05-12
  • Standard earnings release filing for Q1 2026 fiscal quarter ended March 31, 2026, with the company disclosing financial results and business outlook through a press release.
  • Information is furnished rather than filed, meaning it is not subject to Section 18 liabilities and will not be automatically incorporated into future SEC filings unless expressly referenced.
  • CEO Yuval Cohen signed the filing, indicating official company authorization and management's responsibility for the disclosed information and business guidance.
Filing tone (AI): Neutral
View Original Filing →

Other reports for Corbus Pharmaceuticals Holdings, Inc.

Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.